Boehringer Ingelheim, Evotec and bioMérieux launch AUROBAC THERAPEUTICS
Published on
The resulting company, AUROBAC THERAPEUTICS SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.